Take a moment to view our events and clinical presentations.

Posters: American Society of Nephrology Kidney Week Meeting, October 2018

October 2018

The following posters were presented at the American Society of Nephrology Kidney Week 2018 Annual Meeting in San Diego, California:

Geoffrey A. Block, M.D., CCRI, Director of Clinical Research at Denver Nephrology, presented One-Year Data Report from “CARDINAL”: A Phase 2/3 Study of Bardoxolone Methyl in Patients with Alport Syndrome.

Geoffrey A. Block, M.D., CCRI, Director of Clinical Research at Denver Nephrology, presented Analyses from a Phase 2 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with IgA Nephropathy: The PHOENIX Study.

Pablo Pergola, M.D., Ph.D., Research Director at Renal Associates PA in San Antonio, TX, presented Analyses from a Phase 2 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease: The PHOENIX Study.

Arnold L. Silva, M.D., Ph.D., Director of Clinical Research at Boise Kidney and Hypertension Institute, presented Analyses from a Phase 2 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Type 1 Diabetes: The PHOENIX Study.

To view or download a PDF of these posters, click here.

Press Release: Reata Announces Positive Phase 2 Data for Bardoxolone Methyl in CKD caused by Alport Syndrome and Autosomal Dominant Polycystic Kidney Disease, July 2018

July, 2018

  • Statistically significant improvement in kidney function maintained in Alport syndrome patients after 48 weeks of treatment
  • Statistically significant retained benefit of 4.1 ml/min in Alport syndrome patients following 48 weeks of treatment and 4 weeks of drug withdrawal
  • Statistically significant improvement in kidney function observed in ADPKD patients after 12 weeks of treatment

To read the full press release, click here.

Webcast: Management Call to Discuss Phase 2 CARDINAL and PHOENIX Updates, July 2018

July, 2018

For the PDF version of the presentation, click here.

For a replay of the teleconference call (MP3), click here.


Poster: Pablo Pergola, M.D., Ph.D., Renal Associates, San Antonio, TX, at European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) in Copenhagen, Denmark, May 2018

May 2018
Reata’s interim results from the PHOENIX trial were presented by Dr. Pablo Pergola, Initial Results from a Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy, at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Copenhagen, Denmark 2018.

Presentation: Christoph Wanner, M.D., Professor of Medicine and Chief of Nephrology and Hypertension Division at the University Hospital of Würzburg, Germany, at European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) in Copenhagen, Denmark, May 2018

May 2018
Reata’s post-hoc analysis from BEACON, a Phase 2 trial in Stage 4 CKD and Diabetes, were presented by Dr. Christoph Wanner, Chief of the Nephrology and Hypertension Division at University Hospital in Würzburg, Germany, on the morning of May 25, 2018: Bardoxolone Methyl Prevents eGFR Decline in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes ─ Post-hoc Analyses from BEACON, at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Copenhagen, Denmark 2018.

Poster: Professor Peter Rossing, MD, DMSc, Director of Research of the Steno Diabetes Center in Copenhagen, Denmark, at European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) in Copenhagen, Denmark, May 2018.

May 2018
Professor Peter Rossing, MD, DMSc, presented the poster: Effect of Bardoxolone Methyl on Urinary Albumin in Patients with Type 2 Diabetes and Chronic Kidney Disease: Post-hoc Analyses from BEAM and BEACON, at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Copenhagen, Denmark 2018.

Poster: Professor Peter Rossing, MD, DMSc, Director of Research of the Steno Diabetes Center in Copenhagen, Denmark, at European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) in Copenhagen, Denmark, May 2018.

May 2018
Professor Peter Rossing, MD, DMSc, presented the poster: Decreases in Weight with Bardoxolone Methyl in Obese Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes – Post-Hoc Analyses from BEACON, at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Copenhagen, Denmark 2018.

Poster: Colin Meyer, MD, Reata Pharmaceutical’s Chief Medical Officer at European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) in Copenhagen, Denmark, May 2018.

May 2018
Colin J. Meyer, Reata Pharmaceutical’s CMO, presented the poster: Two-Year Durability of Improvements in eGFR with Bardoxolone Methyl in Patients with Pulmonary Arterial Hypertension: The LARIAT Study, at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Copenhagen, Denmark 2018.

Webcast: Update on Kidney Function Data the LARIAT Study, February 2018

February 2018

Reata management discussed the long-term follow up portion of the LARIAT study demonstrating that pulmonary arterial hypertension (PAH) patients treated with bardoxolone methyl (bardoxolone) experienced kidney function improvements that were durable for two years and not associated with adverse outcomes. The two-year duration of sustained eGFR improvement in LARIAT is twice as long as Reata has previously reported for bardoxolone and supports the rationale for Reata’s ongoing CARDINAL and PHOENIX programs in rare forms of chronic kidney disease.

For the PDF version of the presentation, click here.

For a replay of the teleconference call (MP3), click here.

Presentation: Bardoxolone Methyl Overview, November 2017

November 2017

For an overview of Reata’s development program in chronic kidney disease, see Bardoxolone Methyl Overview.

Webcast: Program Update of Bardoxolone Methyl in CKD, November 2017

November 2017

Reata management provided a Program Update of Bardoxolone Methyl in CKD in a webcast teleconference call that reviewed the Phase 2 results of CARDINAL and TSUBAKI data, other pharmacologic effects of bardoxolone in CKD patients, and discussed the PHOENIX program.

For a replay of the teleconference call (MP3), please click here.

Presentation & Poster: Primary Phase 2 Analyses from CARDINAL: A Phase 2/3 Study of Bardoxolone Methyl in Patients with Alport Syndrome, American Society of Nephrology Kidney Week Meeting, November 2017

November 2017

Geoffrey A. Block, M.D., CCRI, director of clinical research at Denver Nephrology, presented, Primary Phase 2 Analyses from CARDINAL: A Phase 2/3 Study of Bardoxolone Methyl in Patients with Alport Syndrome, at the American Society of Nephrology Kidney Week 2017 Annual Meeting in New Orleans, Louisiana.

For a poster of the data, Initial Data Report from ‘CARDINAL’: A Phase 2/3 Study of
Bardoxolone Methyl in Patients with Alport Syndrome
, please click here.

Poster: Reata Pharmaceuticals at European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Madrid, Spain 2017

June 2017

Reata Pharmaceuticals exhibited the poster, A Phase 2/3 Study of Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome, at the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) Madrid, Spain 2017.

Presentation: Dr. David Lynch, Director of the Friedreich’s Ataxia Program at Children’s Hospital of Philadelphia, at the Patient-Focused Drug Development meeting hosted by FARA, 2017

June 2017

Reata’s results from MOXIe Part 1, a Phase 2 trial in Friedreich’s ataxia, were presented by Dr. David Lynch, Director of the Friedreich’s Ataxia Program at Children’s Hospital of Philadelphia, during the afternoon of June 2, 2017 at 3:00pm EDT, after completion of the Patient-Focused Drug Development meeting hosted by FARA: Safety, Efficacy, and Pharmacodynamics of Omav (Omaveloxolone) in Friedreich’s Ataxia Patients (MOXIe Trial): Part 1 Results.


Poster: R. James White, M.D., Ph.D., School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, at American Thoracic Society (ATS) in Washington DC, 2017

May 2017

Reata Pharmaceuticals presented interim data from extension phase of the LARIAT study of bardoxolone methyl in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD) at the annual meeting of the 2017 American Thoracic Society (ATS) in Washington DC, USA. The presentation, Interim Analysis of the Efficacy and the Safety of Bardoxolone Methyl in Patients with Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD) (The LARIAT Study), was presented by R. James White, M.D., Ph.D., from the School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY.

Poster: Greg Miller, Ph.D., Reata Pharmaceuticals Principal Scientist, at American Thoracic Society (ATS) in Washington DC, 2017

May 2017

Reata Pharmaceuticals presented the preclinical rationale for developing bardoxolone methyl for pulmonary hypertension at the annual meeting of the 2017 American Thoracic Society (ATS) in Washington DC, USA. The presentation, Bardoxolone Methyl Inhibits Proliferation of Human Pulmonary Arterial Smooth Muscle Cells Cultured Under Hypoxic Conditions, was presented by Greg Miller, Ph.D., Principal Scientist at Reata Pharmaceuticals.

Poster: R. James White, M.D., Ph.D., School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, at American College of Rheumatology (ACR) in Washington DC, 2016

November 2016

Reata Pharmaceuticals presented interim data from extension phase of the LARIAT study of bardoxolone methyl in Pulmonary Arterial Hypertension at the annual meeting of the 2016 American College of Rheumatology (ACR) in Washington DC, USA. The presentation, Bardoxolone Methyl Produces Durable Benefits in Participants with Pulmonary Arterial Hypertension: Data from an Open-Label Extension Study, was presented by R. James White, M.D., Ph.D., from the School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY.

Video: Scleroderma News Interviews Colin Meyer, M.D., at Systemic Sclerosis World Conference in Lisbon, Portugal, 2016

February 2016

Colin Meyer, M.D., Reata Pharmaceuticals’ Chief Medical Officer, talks with Scleroderma News correspondent Dr. Ana de Barros about LARIAT, a Phase 2 study of bardoxolone methyl in patients with pulmonary hypertension (PH), and CATALYST, a Phase 3 study of bardoxolone methyl in patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) at the 4th Systemic Sclerosis World Conference in Lisbon, Portugal, from February 18-20, 2016.

LARIAT and CATALYST

Presentation: Ronald Oudiz, M.D., Professor of Medicine, David Geffen School of Medicine at UCLA, at CHEST 2015 in Montreal, Canada

October 2015

Reata Pharmaceuticals announced initial data from the LARIAT trial evaluating bardoxolone methyl in pulmonary arterial hypertension (PAH) patients at the annual meeting of the 2015 American College of Chest Physicians (CHEST) in Montreal, Canada. The presentation, Initial Data Report from “LARIAT”: a Phase 2 Study of Bardoxolone Methyl in PAH Patients on Stable Background Therapy, was presented by Ronald Oudiz, M.D., Professor of Medicine, David Geffen School of Medicine at UCLA. Dr. Oudiz is Director of the Pulmonary Hypertension Center and a Faculty Cardiologist at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center in Southern California.

LARIAT

Presentation: Colin Meyer, M.D., Reata Pharmaceuticals’ Chief Medical Officer, at the International Ataxia Research Conference 2015

March 2015

Colin Meyer, M.D., Reata Pharmaceuticals’ Chief Medical Officer, delivered a presentation titled, Rationale and Design of a Clinical Study of RTA 408 in Patients with Friedreich’s Ataxia, at the International Ataxia Research Conference 2015 in Windsor, England, co-hosted by Friedreich’s Ataxia Research Alliance (FARA) and International Ataxia Research Organizations.

fara

Video: Reata Pharmaceuticals Clinical Trial in FA for RTA 408

March 2015

Reata Pharmaceuticals has launched a clinical trial in Friedreich’s ataxia (FA) for our drug RTA 408. Our Chief Medical Officer, Dr. Colin Meyer, had the opportunity to talk with the Friedreich’s Ataxia Research Alliance (FARA) about Reata and RTA 408.

fara

Presentation: Investigation of Serious Adverse Events in Bardoxolone Methyl Patients in BEACON (ERA-EDTA, June 2014)

June 2014

Colin Meyer, M.D., Reata’s Chief Medical Officer, presented a Late-Breaking Presentation at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress in Amsterdam in June 2014, Investigation of Serious Adverse Events in Bardoxolone Methyl Patients in BEACON, that discusses the clinical profile, risk factors, and likely mechanistic explanation of key adverse events uncovered in the BEACON trial.